Bufalin/Huachansu Cancer Research Results

BF, Bufalin/Huachansu: Click to Expand ⟱
Features:
Bufalin/Huachansu is a component from Chinese toad venom. Bufalin is classified as a cardiac glycoside, specifically a type of bufadienolide.

Pathways:
-release of cytochrome c and subsequent activation of caspases
-enhance the expression of death receptors
-inhibit the PI3K/Akt/mTOR
-modulate the MAPK/ERK pathway
-inhibit NF-κB signaling
-induce cell cycle arrest at different checkpoints (commonly G0/G1 or G2/M)
-elevate intracellular ROS levels
-interfere with the Wnt/β-catenin signaling pathway
-modulate autophagy, a process that can either promote cell survival or lead to cell death
-Stabilization or activation of p53

Bufalin — Bufalin is a steroidal cardiotonic toxin and anticancer lead compound, classically isolated from toad venom (ChanSu / Huachansu) and belonging to the bufadienolide subclass of cardiac glycosides. It is commonly abbreviated BF. In cancer research, bufalin is best understood as a pleiotropic signaling disruptor whose most central pharmacology is linked to Na+/K+-ATPase engagement, with downstream effects on survival signaling, mitochondrial death pathways, redox stress, stemness, invasion, and therapy resistance.

Primary mechanisms (ranked):

  1. Na+/K+-ATPase targeting with disruption of pump-linked oncogenic signaling and, in some models, α1-subunit destabilization/degradation.
  2. Mitochondria-linked apoptosis with cytochrome c release, caspase activation, and loss of survival signaling.
  3. Suppression of PI3K/Akt/mTOR and related pro-survival nodes, with context-dependent effects on ERK, NF-κB, and STAT3-linked programs.
  4. ROS elevation with stress-kinase activation (especially JNK/p38) and redox-dependent death signaling; this is important but usually downstream/secondary rather than the first initiating event.
  5. Cell-cycle arrest and mitotic disruption, including Aurora kinase-related effects in some tumor models.
  6. Inhibition of stemness, EMT, migration, invasion, angiogenesis, and drug-resistance phenotypes, including Wnt/β-catenin- and YAP-associated programs in selected cancers.
  7. Autophagy modulation, which can be cytoprotective or cytotoxic depending on model and schedule.

Bioavailability / PK relevance: Translation is constrained by poor water solubility, low/variable bioavailability of bufadienolides, short apparent plasma persistence in human Huachansu infusion studies, and a narrow therapeutic window typical of cardiac glycosides. CYP3A-mediated metabolism and CYP3A4 inhibition/time-dependent inactivation raise drug-interaction concern. Delivery optimization by nanoparticles, prodrugs, and formulation engineering is mechanistically relevant, not merely cosmetic.

In-vitro vs systemic exposure relevance: Concentration-driven. Many mechanistic cancer studies report activity in low-nanomolar to submicromolar ranges, which is closer to plausibility than for many phytochemicals; however, human plasma bufalin levels reported during Huachansu infusion were only low ng/mL and showed little accumulation, so many higher in-vitro conditions likely exceed sustained clinically achieved free exposure. Any interpretation should therefore prioritize low-nanomolar findings and delivery-enabled tumor exposure rather than high-concentration cell-culture effects.

Clinical evidence status: Preclinical to small-human evidence only. There is substantial in-vitro and animal evidence, plus early Huachansu clinical studies in China and a phase I/II development path, but no convincing randomized evidence that bufalin-containing therapy improves major cancer outcomes. Current status is best described as experimental / adjunct-oriented rather than established anticancer therapy.

Mechanistic translation matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Na+/K+-ATPase signalosome ↓ pump-linked oncogenic signaling; ↓ proliferation; apoptosis trigger ↓ ubiquitous pump function; cardiotoxicity risk P-R Upstream target engagement Most central mechanism. Bufalin behaves as a cardiac glycoside/bufadienolide with strong relevance to ATP1A1-linked signaling and tumor vulnerability, but normal-tissue exposure limits selectivity.
2 Mitochondria and intrinsic apoptosis ↑ cytochrome c release; ↑ caspases; ↑ mitochondrial dysfunction ↔ to ↓ tolerance window R-G Cell death induction Robust across many tumor models and commonly downstream of Na+/K+-ATPase disruption, ROS stress, and survival-pathway collapse.
3 PI3K Akt mTOR survival axis ↓ ↔ to ↓ R-G Anti-survival signaling One of the most repeatedly reported downstream axes. Often linked to apoptosis sensitization, growth arrest, and resistance reversal.
4 NF-κB inflammatory survival signaling ↓ ↔ to ↓ R-G Reduced survival and inflammatory tone Usually a secondary convergence node rather than the first molecular hit.
5 Mitochondrial ROS increase ↑ (dose-dependent) ↑ toxicity risk R Stress amplification Mechanistically important in several models, especially where JNK/p38 activation and autophagy-mediated death are observed. Not universal as the dominant initiating event.
6 JNK p38 stress kinase axis ↑ ↔ R-G Pro-apoptotic stress signaling Often coupled to ROS elevation and mitochondrial injury.
7 ERK MAPK signaling ↓ or ↔ (context-dependent) ↔ R-G Growth signaling modulation Reported direction varies by model; best treated as context-dependent rather than universally suppressed.
8 Cell-cycle and mitotic machinery ↑ G0/G1 or G2/M arrest; ↓ Aurora activation ↔ to ↓ proliferative tissues G Cytostasis and mitotic disruption Relevant in multiple cancers; checkpoint phenotype varies by model.
9 Wnt β-catenin stemness axis ↓ stemness; ↓ EMT; ↓ invasion ↔ G Anti-metastatic differentiation pressure Important in selected resistant and stem-like states rather than universally core.
10 Autophagy program ↑ or ↓ (context-dependent) ↔ R-G Death modulator Can either support survival or contribute to death. Interpretation must stay model-specific.
11 Chemosensitization and resistance reversal ↑ sensitivity ↔ G Adjunct potential Preclinical evidence is strong enough to keep this high in translational interest, but human confirmation is still weak.
12 Clinical Translation Constraint Exposure limited Systemic toxicity relevant G Therapeutic window constraint Poor solubility, formulation dependence, short plasma persistence, CYP3A liability, and cardiac-glycoside toxicity remain the main barriers to direct clinical deployment.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Scientific Papers found: Click to Expand⟱
5715- BF,    Bufalin for an innovative therapeutic approach against cancer
- Review, Var, NA
selectivity↑, TumCP↓, TumCCA↓, TumCD↑, Apoptosis↑, TumAuto↑, TumMeta↓, TumCMig↓, TumCI↓, angioG↓, CSCs↓,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
5717- BF,  Chemo,  GEM,    Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas
- Trial, Var, NA
OS∅,
5718- BF,    Bufalin inhibits CYP3A4 activity in vitro and in vivo
- in-vivo, Nor, NA
CYP3A4↓, Apoptosis↑, AntiTum↑,
5719- BF,    Bufalin inhibits the proliferation of lung cancer cells by suppressing Hippo-YAP pathway
- in-vitro, Lung, NA
TumCP↓, Hippo↓, YAP/TEAD↓,
5720- BF,    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway
- in-vitro, NSCLC, NA
STAT3↓, CycB/CCNB1↓, CDC2↓, Mcl-1↓, survivin↓, VEGF↓, Bcl-2↓, BAX↑, Casp3↑,
5721- BF,    Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
- in-vitro, BC, NA
CSCs↓, TumCCA↑, cMyc↓, cycD1/CCND1↓, CDK4↓, MMP↓, Casp↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, SOX2↓, Wnt↓, β-catenin/ZEB1↓, EGFR↓,
5722- BF,    Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells
- in-vitro, PC, PANC1
Apoptosis↑, TumCCA↑, HSP27↓, p‑Akt↓, proCasp3↑, proCasp9↑, Bcl-2↝, BAX↝, eff↑,
5723- BF,    Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A
- Study, NA, NA
other↝,
5724- BF,    A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice
- vitro+vivo, Lung, A549
Apoptosis↑, Casp3↑, cl‑PARP↑,
5725- BF,  TMZ,    Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide
- in-vitro, GBM, NA
TumCG↓, TumCP↓, CSCs↓, cl‑Casp3↑, PARP↑, Telomerase↓, eff↑,
5726- BF,    Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain
- Review, neuroblastoma, SK-N-BE
Apoptosis↑, TumCP↓, TumCMig↓, MMP↓, ROS↑, ETC↓, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, eff↓, TumCG↓, Ki-67↓, PCNA↓,
5727- BF,    Bufalin Inhibits Proliferation and Induces Apoptosis in Osteosarcoma Cells by Downregulating MicroRNA-221
- in-vitro, OS, U2OS
TumCP↓, Apoptosis↑, ROS↑, miR-221↓,
5728- BF,    Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, TumCCA↑, Bcl-2↝, BAX↝, Cyt‑c↝, Casp3↝, PARP↝, P21↝, cycD1/CCND1↝, COX2↝, p‑VEGFR2↓, EGFR↓, Akt↓, NF-kB↓, p44↓,
5729- BF,    Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling
- in-vitro, Lung, NA
TumCCA↑, Apoptosis↑, TumCG↓, EGFR↓, PI3K↓, Akt↓, mTOR↓, P70S6K↓,
5730- BF,    Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
- in-vitro, BC, MCF-7 - in-vitro, Lung, A549
other↝, TumCP↓,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   ETC↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   CYP3A4↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 8,   BAX↑, 2,   BAX↝, 2,   Bcl-2↓, 2,   Bcl-2↝, 2,   Casp↑, 1,   Casp3↑, 2,   Casp3↝, 1,   cl‑Casp3↑, 2,   proCasp3↑, 1,   proCasp9↑, 1,   Cyt‑c↝, 1,   Hippo↓, 1,   Mcl-1↓, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↝, 2,  

Protein Folding & ER Stress ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

PARP↑, 1,   PARP↝, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycD1/CCND1↝, 1,   P21↝, 1,   TumCCA↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CD44↓, 1,   CSCs↓, 3,   mTOR↓, 1,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 1,   SOX2↓, 1,   STAT3↓, 1,   TumCG↓, 3,   Wnt↓, 1,  

Migration ⓘ

Ki-67↓, 1,   miR-221↓, 1,   p44↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 7,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 3,   VEGF↓, 1,   p‑VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↝, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↓, 1,   eff↑, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 3,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS?, 1,   OS∅, 1,   QoL↑, 1,   toxicity↓, 1,  
Total Targets: 79

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:49  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page